Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies

Med Decis Making. 2006 Nov-Dec;26(6):633-5; author reply 636-7. doi: 10.1177/0272989X06295363.
No abstract available

Publication types

  • Comment

MeSH terms

  • Alendronate / adverse effects
  • Alendronate / economics*
  • Alendronate / therapeutic use
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / economics*
  • Bone Density Conservation Agents / therapeutic use
  • Cost-Benefit Analysis
  • Decision Support Techniques*
  • Estrogen Replacement Therapy / adverse effects
  • Estrogen Replacement Therapy / economics*
  • Female
  • Humans
  • Mass Screening / economics
  • Middle Aged
  • Osteoporosis, Postmenopausal / economics*
  • Osteoporosis, Postmenopausal / mortality
  • Raloxifene Hydrochloride / adverse effects
  • Raloxifene Hydrochloride / economics*
  • Raloxifene Hydrochloride / therapeutic use
  • Selective Estrogen Receptor Modulators / adverse effects
  • Selective Estrogen Receptor Modulators / economics*
  • Selective Estrogen Receptor Modulators / therapeutic use
  • Venous Thrombosis / chemically induced*
  • Venous Thrombosis / economics*
  • Venous Thrombosis / mortality

Substances

  • Bone Density Conservation Agents
  • Selective Estrogen Receptor Modulators
  • Raloxifene Hydrochloride
  • Alendronate